Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06400368 · ClinicalTrials.gov registry record
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
A clinical trial of Alzheimer Disease and Mild Cognitive Impairment, sponsored by NeuroVision Imaging.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06400368 is a study of Alzheimer Disease and Mild Cognitive Impairment that is actively recruiting participants, run by NeuroVision Imaging. The registered enrollment target is 200 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06400368, a study of Alzheimer Disease and Mild Cognitive Impairment, is actively recruiting participants, sponsored by NeuroVision Imaging.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
Conditions Studied
Study Locations (1)
California
- Sutter Health - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2026-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06400368
The ClinicalTrials.gov registry entry for NCT06400368 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (93% lower). The listed sponsor is NeuroVision Imaging, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06400368 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06400368 about?
NCT06400368 is a clinical study titled "Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease". This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
What is the current status of trial NCT06400368?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2024-04-24. Estimated completion is 2026-04.
What conditions does trial NCT06400368 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment.
Who is sponsoring clinical trial NCT06400368?
This trial is sponsored by NeuroVision Imaging, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06400368 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.